Literature DB >> 16801435

Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy.

Morgan Hakki1, Janet F Staab, Kieren A Marr.   

Abstract

Clinical failure associated with reduced susceptibility to caspofungin has been described in Candida albicans and C. parapsilosis. We report a case of Candida krusei infection that progressed despite caspofungin therapy. Reduced microbial susceptibility to all three echinocandins (caspofungin, anidulafungin, and micafungin) was noted but was not associated with mutations in FKS1.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16801435      PMCID： PMC1489805          DOI： 10.1128/AAC.00148-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  9 in total

1.  Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species.

Authors:  Frank C Odds; Mary Motyl; Roberto Andrade; Jacques Bille; Emilia Cantón; Manuel Cuenca-Estrella; Amanda Davidson; Christian Durussel; David Ellis; Elyse Foraker; Annette W Fothergill; Mahmoud A Ghannoum; Robert A Giacobbe; Miguel Gobernado; Rosemary Handke; Michel Laverdière; Wendy Lee-Yang; William G Merz; Luis Ostrosky-Zeichner; Javier Pemán; Sophia Perea; John R Perfect; Michael A Pfaller; Laurie Proia; John H Rex; Michael G Rinaldi; Juan-Luis Rodriguez-Tudela; Wiley A Schell; Christine Shields; Deanna A Sutton; Paul E Verweij; David W Warnock
Journal:  J Clin Microbiol       Date:  2004-08       Impact factor: 5.948

2.  Hsp90 potentiates the rapid evolution of new traits: drug resistance in diverse fungi.

Authors:  Leah E Cowen; Susan Lindquist
Journal:  Science       Date:  2005-09-30       Impact factor: 47.728

3.  Sensititre YeastOne caspofungin susceptibility testing of Candida clinical isolates: correlation with results of NCCLS M27-A2 multicenter study.

Authors:  Emilia Cantón; Javier Pemán; Miguel Gobernado; Elena Alvarez; Fernando Baquero; Ramón Cisterna; Joaquina Gil; Estrella Martín-Mazuelos; Carmen Rubio; Aurora Sánchez-Sousa; Carmen Serrano
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

4.  Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates.

Authors:  S Park; R Kelly; J Nielsen Kahn; J Robles; M-J Hsu; E Register; W Li; V Vyas; H Fan; G Abruzzo; A Flattery; C Gill; G Chrebet; S A Parent; M Kurtz; H Teppler; C M Douglas; D S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

5.  Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-beta-D-glucan synthase inhibitors.

Authors:  C M Douglas; J A D'Ippolito; G J Shei; M Meinz; J Onishi; J A Marrinan; W Li; G K Abruzzo; A Flattery; K Bartizal; A Mitchell; M B Kurtz
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

6.  Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis.

Authors:  Varsha Moudgal; Tania Little; Dina Boikov; Jose A Vazquez
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

7.  Comparison of PCR- and HinfI restriction endonuclease-based methods for typing of Candida krusei isolates.

Authors:  Banu Sancak; John H Rex; Enuo Chen; Kieren Marr
Journal:  J Clin Microbiol       Date:  2004-12       Impact factor: 5.948

8.  Caspofungin.

Authors:  Stanley C Deresinski; David A Stevens
Journal:  Clin Infect Dis       Date:  2003-05-19       Impact factor: 9.079

9.  Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis.

Authors:  Steve Hernandez; José L López-Ribot; Laura K Najvar; Dora I McCarthy; Rosie Bocanegra; John R Graybill
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191
  9 in total
  58 in total

1.  Canadian clinical practice guidelines for invasive candidiasis in adults.

Authors:  Eric J Bow; Gerald Evans; Jeff Fuller; Michel Laverdière; Coleman Rotstein; Robert Rennie; Stephen D Shafran; Don Sheppard; Sylvie Carle; Peter Phillips; Donald C Vinh
Journal:  Can J Infect Dis Med Microbiol       Date:  2010       Impact factor: 2.471

2.  Breakthrough invasive candidiasis in patients on micafungin.

Authors:  Christopher D Pfeiffer; Guillermo Garcia-Effron; Aimee K Zaas; John R Perfect; David S Perlin; Barbara D Alexander
Journal:  J Clin Microbiol       Date:  2010-04-26       Impact factor: 5.948

3.  Evaluating retinal toxicity of intravitreal caspofungin in the mouse eye.

Authors:  Deb K Mojumder; Francis A Concepcion; Shil K Patel; Andrew J Barkmeier; Petros E Carvounis; John H Wilson; Eric R Holz; Theodore G Wensel
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-05-26       Impact factor: 4.799

Review 4.  [Strategies for antifungal treatment failure in intensive care units].

Authors:  C Arens; M Bernhard; C Koch; A Heininger; D Störzinger; T Hoppe-Tichy; M Hecker; B Grabein; M A Weigand; C Lichtenstern
Journal:  Anaesthesist       Date:  2015-09       Impact factor: 1.041

5.  Echinocandin failure case due to a previously unreported FKS1 mutation in Candida krusei.

Authors:  Rasmus Hare Jensen; Ulrik Stenz Justesen; Annika Rewes; David S Perlin; Maiken Cavling Arendrup
Journal:  Antimicrob Agents Chemother       Date:  2014-03-31       Impact factor: 5.191

6.  In vitro pharmacodynamics of anidulafungin and caspofungin against Candida glabrata isolates, including strains with decreased caspofungin susceptibility.

Authors:  Jason Cota; Michael Carden; John R Graybill; Laura K Najvar; David S Burgess; Nathan P Wiederhold
Journal:  Antimicrob Agents Chemother       Date:  2006-08-28       Impact factor: 5.191

7.  Acquired echinocandin resistance in a Candida krusei isolate due to modification of glucan synthase.

Authors:  Jennifer Nielsen Kahn; Guillermo Garcia-Effron; Ming-Jo Hsu; Steven Park; Kieren A Marr; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2007-02-26       Impact factor: 5.191

8.  A Ser678Pro substitution in Fks1p confers resistance to echinocandin drugs in Aspergillus fumigatus.

Authors:  Eleusa Maria F Rocha; Guillermo Garcia-Effron; Steven Park; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2007-08-27       Impact factor: 5.191

9.  Comparative in vitro activities of caspofungin and micafungin, determined using the method of the European Committee on Antimicrobial Susceptibility Testing, against yeast isolates obtained in France in 2005-2006.

Authors:  E Dannaoui; O Lortholary; D Raoux; M E Bougnoux; G Galeazzi; C Lawrence; D Moissenet; I Poilane; D Hoinard; F Dromer
Journal:  Antimicrob Agents Chemother       Date:  2007-12-10       Impact factor: 5.191

10.  Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints.

Authors:  Guillermo Garcia-Effron; Steven Park; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.